{"organizations": [], "uuid": "5202933207c149de22c143369d51bc88eaa4f842", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abide-and-celgene-enter-worldwide/brief-abide-and-celgene-enter-worldwide-license-agreement-for-abx-1772-idUSFWN1RA0D1", "country": "US", "domain_rank": 408, "title": "BRIEF-Abide And Celgene Enter Worldwide License Agreement For ABX-1772", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T14:24:00.000+03:00", "replies_count": 0, "uuid": "5202933207c149de22c143369d51bc88eaa4f842"}, "author": "", "url": "https://www.reuters.com/article/brief-abide-and-celgene-enter-worldwide/brief-abide-and-celgene-enter-worldwide-license-agreement-for-abx-1772-idUSFWN1RA0D1", "ord_in_thread": 0, "title": "BRIEF-Abide And Celgene Enter Worldwide License Agreement For ABX-1772", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "celgene", "sentiment": "negative"}, {"name": "celgene corp", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "  Updated 10 minutes ago BRIEF-Abide And Celgene Enter Worldwide License Agreement For ABX-1772 Reuters Staff \n  Celgene Corp: \n* ABIDE AND CELGENE ENTER WORLDWIDE LICENSE AGREEMENT FOR ABX-1772 \n* ‍ABIDE THERAPEUTICS SAYS GRANTED CELGENE AN EXCLUSIVE WORLDWIDE LICENSE FOR ABX-1772, A PRECLINICAL DRUG CANDIDATE DISCOVERED BY ABIDE​ \n* ‍ABIDE THERAPEUTICS SAYS ABIDE RECEIVED UNDISCLOSED PAYMENT AND WILL BE ENTITLED TO CERTAIN MILESTONE PAYMENTS AND ROYALTIES ON COMMERCIAL SALES​ \n* ‍ABIDE THERAPEUTICS SAYS ABIDE HAS REGAINED EX-US RIGHTS TO ABX-1431 FROM CELGENE​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-28T14:24:00.000+03:00", "crawled": "2018-03-28T14:48:22.013+03:00", "highlightTitle": ""}